Meeting
2016 ASCO Annual Meeting
BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
Authors
Julia C. Chisholm
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Julia C. Chisholm , Johannes H. Merks , Michela Casanova , Gianni Bisogno , Daniel Orbach , Jean-Claude Gentet , Anne-Sophie Thomassin Defachelles , Pascal B. Chastagner , Steve Lowis , Milind Ronghe , Kieran McHugh , Rick R. van Rijn , Magalie Hilton , Jeanette Bachir , Sabine Fürst-Recktenwald , Birgit Geoerger , Odile Oberlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT00643565
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11054)
DOI
10.1200/JCO.2016.34.15_suppl.11054
Abstract #
11054
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS).
First Author: Julia C. Chisholm
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2023 ASCO Annual Meeting
Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.
First Author: Luciana Vinti
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz